Those NDA plans Odonate had for mid-'21? They're be­ing scrapped — along with the en­tire biotech — in a sud­den im­plo­sion

Last sum­mer, San Diego-based Odonate $ODT CEO Kevin Tang en­thu­si­as­ti­cal­ly sought to bol­ster in­vestors’ en­thu­si­asm for the com­pa­ny with what the biotech called “a po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.